Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use

International Journal of Pharmaceutics

Volumn 325, Issue 1-2, 2006, Pages 124-131

  Limayem Blouza, I ^a,b   Charcosset, C ^a   Sfar, S ^b   Fessi, H ^a  

^a CPE LYON   (France)

^b UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

Formulation; Membrane contactor; Nanocapsules; Nanoprecipitation; Optimisation; Spironolactone

Indexed keywords

NANOCAPSULE; SPIRONOLACTONE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; DRUG USE; ENCAPSULATION; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; STOMACH JUICE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR WEIGHT; NANOCAPSULES; NANOTECHNOLOGY; OILS; PARTICLE SIZE; POLOXAMER; POLYESTERS; SOLUBILITY; SOLVENTS; SPIRONOLACTONE; TIME FACTORS;

EID: 33750269368     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.06.022     Document Type: Article

References (28)

1. Allen L.V., and Erickson M.A. Stability of ketonazole, metolazone, metronidazole, procainamide, hydrochloride and spironolactone in extemporaneously compounded oral liquids. Am. J. Health-Syst. Pharm. 53 (1996) 2073-2078
2. Atkinson S.A., Shah J.K., McGee C., and Steele B.T. Mineral excretion in premature infants receiving various diuretic therapies. J. Pediatr. 113 (1988) 540-545
3. Charcosset C., and Fessi H. Preparation of nanoparticles with a membrane contactor. J. Membr. Sci. 266 (2005) 115-120
4. Charcosset H., Limayem I., and Fessi H. The membrane emulsification process-a review. J. Chem. Technol. Biot. 79 (2004) 209-218
5. Chaumeil J.C. Micronization: a method of improving the bioavailability of poorly soluble drugs. Meth. Find. Exp. Clin. Pharm. 20 (1998) 211-215
6. Chorny M., Fishbein I., Danenberg H.D., and Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J. Contr. Rel. 83 (2002) 389-400
7. Christov N.C., Ganchev D.N., Vassileva N.D., Denkov N.D., Danov K.D., and Kralchevsky P.A. Capillary mechanisms in membrane emulsification: oil-in-water emulsions stabilized by Tween 20 and milk proteins. Colloids Surf. 209 (2002) 83-104
8. Couvreur P., Barratt G., Fattal E., Legrand P., and Vautier C. Nanocapsules technology: a review. Crit. Rev. Ther. Drug 19 (2002) 99-134
9. Couvreur P., Dubernet C., and Puisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Pharm. Biopharm. 41 (1995) 2-13
10. Fessi, H., Devissaguet, J.P., Puisieux, F., Thies, C., 1988. Procédé de préparation de systèmes colloïdaux dispersibles d'une substance, sous forme de nanoparticules, French Patent 2,608,988.
11. Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., and Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55 (1989) 25-28
12. Fresta M., Cavallaro G., Giammona G., Wehrli E., and Puglisi G. Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Biomaterials 17 (1996) 751-758
13. Galindo-Rodriguez S.A., Puel F., Briançon S., Alleman E., Doelker E., and Fessi H. Comparative scale-up of three methods for producing ibuprofen-loaded nanoparticles. Eur. J. Pharm. Sci. 25 (2005) 357-367
14. Govender T., Stolnik S., Garnett M.C., Illum L., and Davis H.S. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J. Contr. Rel. 57 (1999) 171-185
15. Guinebretière S., Briançon S., Fessi H., Teodorescu V.S., and Blanchin M.G. Nanocapsules of biodegradable polymers: preparation and characterization by direct high resolution electron microscopy. Mater. Sci. Eng. C21 (2002) 137-142
16. Hebel S.K. Drug Facts and comparisons (2006), Facts and comparisons Inc., St. Louis
17. Kaukonen A.M., Kilpeläinen I., and Mannermaa J.P. Water-soluble β-cyclodextrins in paediatric oral solutions of spironolactone: solubilization and stability of spironolactone in solutions of β-cyclodextrin derivatives. Int. J. Pharm. 159 (1997) 159-170
18. Leff R., and Roberts R. Problems in drug therapy for pediatric patients. Am. J. Hosp. Pharm. 44 (1987) 865-869
19. Legrand P., Barratt G., Mosqueira V., Fessi H., and Devissaguet J.P. Polymeric nanocapsules as drug delivery systems. S.T.P. Pharma Sci. 9 (1999) 411-418
20. Magenheim B., and Benita S. Nanoparticle characterization: a comprehensive physicochemical approach. S.T.P. Pharma Sci. 1 (1991) 221-241
21. Mathur L.K., and Wickman A. Stabillity of extemporaneously compounded spironolactone suspensions. Am. J. Hosp. Pharm. 46 (1989) 2040-2042
22. Nahata M.C., Morosco R.S., and Hipple T.F. Stability of spironolactone in an extemporaneously prepared suspension at two temperatures. Ann. Pharmacother. 27 (1993) 1198-1199
23. Peterson G.M., Meaney M.F., Reid C.A., and Taylor G.R. Stability of extemporaneously prepared mixtures of metoprolol and spironolactone. Aust. J. Hosp. Pharm. 19 (1989) 344-351
24. Pramar Y., Gupta V.D., and Bethea C. Development of a stable oral fluid dosage form of spironolactone. J. Clin. Pharm. Ther. 17 (1992) 245-248
25. Soliman O., Kimura K., Hirayama F., Uekama K., El-Sabbagh H., Abd El-Gawad A., and Hashim F. Amorphous spironolactone-hydroxypropylated cyclodextrine complexes with superior dissolution and oral bioavailability. Int. J. Pharm. 149 (1997) 73-83
26. Standing, Joseph F., and Tuleu C. Paediatric formulations-getting to the heart of the problem. Int. J. Pharm. 300 (2005) 56-66
27. Sutter J.L., and Lau E.P.K. In: Florey I.C. (Ed). Spironolactone, Analytical Profiles of Drug Substances vol. 4 (1975), Academic Press, New York 431-451
28. Xiaohong L., Xianmo D., Minglong Y., Chengdong X., Zhitang H., Yanhua Z., and Wenxiang J. Investigation on process parameters involved in preparation of poly-d,l-lactide-poly (ethylene glycol) microspheres containing Leptospira interogans antigens. Int. J. Pharm. 178 (1999) 245-255